Search results for "BODIES"

showing 10 items of 2217 documents

Antibodies to hepatitis B core antigen in blood donors screened for alanine aminotransferase level and hepatitis non-A, non-B in recipients.

1988

Four-hundred and seventeen patients undergoing open-heart surgery were followed for more than 9 months after transfusion. All 2270 blood units transfused had alanine aminotransferase levels less than or equal to 30 U/l. Blood units positive for antibodies to hepatitis B core antigen (anti-HBc) were more frequently associated with recipient hepatitis non-A, non-B (HNANB) (13.7%) than anti-HBc-negative units (4.2%) (p less than 0.001). The frequency of HNANB among recipients of at least 1 anti-HBc-positive blood unit (8/79, 10.1%) was fivefold greater than among recipients of exclusively anti-HBc-negative blood units (7/338, 2.1%) (p less than 0.01). In this study the exclusion of donors posi…

AdultAdolescentHepatitis Viral HumanImmunologyBlood DonorsAntigenImmunology and AllergyMedicineHumansAlanine aminotransferaseHepatitis B AntibodiesAgedHepatitisbiologybusiness.industryIncidence (epidemiology)virus diseasesTransfusion ReactionAlanine TransaminaseHematologyMiddle Agedmedicine.diseaseHepatitis B Core AntigensHepatitis Cdigestive system diseasesImmunologybiology.proteinBlood unitsAntibodybusinessDonor screeningHepatitis b coreTransfusion
researchProduct

Interferon-Beta Therapy of Multiple Sclerosis Patients Improves the Responsiveness of T Cells for Immune Suppression by Regulatory T Cells

2015

Multiple sclerosis (MS) is an inflammatory autoimmune disease characterized by imbalanced immune regulatory networks, and MS patient-derived T effector cells are inefficiently suppressed through regulatory T cells (Treg), a phenomenon known as Treg resistance. In the current study we investigated T cell function in MS patients before and after interferon-beta therapy. We compared cytokine profile, responsiveness for Treg-mediated suppression ex vivo and evaluated reactivity of T cells in vivo using a humanized mouse model. We found that CD4+ and CD8+ T cells of therapy-naive MS patients were resistant to Treg-mediated suppression. Treg resistance is associated with an augmented IL-6 product…

AdultAdolescentdiagnosisReceptor expressionT cellchemical and pharmacologic phenomenaMice SCIDAntibodies Monoclonal Humanizedmultiple sclerosisT-Lymphocytes RegulatoryCatalysisArticleInorganic ChemistryTCIRG1lcsh:ChemistryInterleukin 21Young AdultImmune systemCytotoxic T cellMedicineAnimalsHumansIL-2 receptorPhysical and Theoretical ChemistryMolecular BiologyT effector cellslcsh:QH301-705.5SpectroscopyImmunosuppression TherapyInflammationtherapybusiness.industryOrganic Chemistryimmune regulationGeneral MedicineInterferon-betaMiddle AgedReceptors Interleukin-6Computer Science ApplicationsTregmedicine.anatomical_structureAnimals Newbornlcsh:Biology (General)lcsh:QD1-999ImmunologyLeukocytes MononuclearbusinessCD8International Journal of Molecular Sciences
researchProduct

Bendamustine with or without rituximab in the treatment of relapsed chronic lymphocytic leukaemia: an Italian retrospective study.

2011

To retrospectively assess the efficacy of bendamustine alone and with rituximab (R-B), 109 patients with relapsed chronic lymphocytic leukaemia (CLL) were enrolled in 24 Italian centres. The median age was 66 years (range 39-85). Forty-three percent of patients had relapsed and 57% were resistant (median previous therapies = 3; range 1-8). Twenty-two patients received bendamustine alone and 87 patients received R-B (median B dosage: 100 mg/m(2) per day, range 90-130 mg/m(2) per day). The overall response rate was 69·6% (complete response 28·6%; partial response 41%), and was significantly higher in patients treated with R-B (P = 0·014) and in those responsive to the previous treatment (P=0·…

AdultAged 80 and overMaleAntineoplastic AgentsMiddle AgedLeukemia Lymphocytic Chronic B-CellAntibodies Monoclonal Murine-DerivedTreatment OutcomeDrug Resistance NeoplasmRecurrenceAntineoplastic Combined Chemotherapy ProtocolsNitrogen Mustard CompoundsBendamustine HydrochlorideDrug EvaluationHumanschronic lymphocytic leukemiaFemaleChronic lymphocytic leukemia; bendamustineBendamustinaEpidemiologic MethodsRituximabAged
researchProduct

SARS-CoV-2 antibody persistence after five and twelve months: A cohort study from South-Eastern Norway

2022

Objectives To assess total antibody levels against Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS CoV-2) spike protein up to 12 months after Coronavirus Disease (COVID-19) infection in non-vaccinated individuals and the possible predictors of antibody persistence. Methods This is the first part of a prospective multi-centre cohort study. Participants The study included SARS-CoV-2 real-time polymerase chain reaction (RT-PCR) positive and negative participants in South-Eastern Norway from February to December 2020. Possible predictors of SARS-CoV-2 total antibody persistence was assessed. The SARS-CoV-2 total antibody levels against spike protein were measured three to five months aft…

AdultAged 80 and overMaleMultidisciplinaryNorwaySARS-CoV-2COVID-19Middle AgedAntibodies ViralCohort StudiesYoung AdultSpike Glycoprotein CoronavirusHumansFemaleVDP::Medisinske Fag: 700Prospective StudiesAged
researchProduct

Thymidylate synthase gene promoter polymorphisms are associated with TSmRNA expressions but not with microsatellite instability in colorectal cancer

2005

Abstract BACKGROUND: Microsatellite instability (MSI) is a biological characteristic of most tumours, being involved in 85% of hereditary non-polyposis colorectal cancer (HNPCC). It also occurs in 10-15% of sporadic colorectal cancers (CRC). HNPCC appears to be caused by germline mutations in mismatch repair (MMR) genes, which are responsible for repairing single base-pair mismatches. MSI is also associated with a better response of CRC to adjuvant chemotherapy with fluoropyrimidines. We investigated any relationship between the MSI status and the TSmRNA expression, the polymorphisms of 5-Fluorouracil (5-FU cellular target, the enzyme thymidylate synthase (TS) and TS expression evaluated by…

AdultAged 80 and overMalePolymorphism GeneticAntibodies MonoclonalThymidylate SynthaseMiddle AgedSettore MED/08 - Anatomia PatologicaImmunohistochemistryGenomic InstabilityHumansFemaleColorectal cancer thymidylate synthase pharmacogenomic microsatellite instability polymorphism molecular therapeutic.RNA Messenger5' Untranslated RegionsColorectal NeoplasmsPromoter Regions GeneticAgedMicrosatellite Repeats
researchProduct

Topographic heterogeneity of amyloid B-protein epitopes in brains with various forms of neuronal ceroid lipofuscinoses suggesting defective processin…

1990

To verify our hypothesis of defective protease inhibitor domains that are encoded by abnormal processing of amyloid precursor protein (APP) in brains of patients with neuronal ceroid lipofuscinoses (NCL), immunohistochemical and cytochemical studies were performed with monoclonal antibodies (mAbs) directed against various domains of APP. For the studies, 22 autopsy brains were used: 12 with different forms of NCL, and 10 control brains. The staining procedure for the avidin-biotin complex (ABC) technique and the postembedding gold-labelled procedure for electron microscopy (EM) were employed. Of all mAbs used for the study, only mAbs generated against amyloid B-protein bound to neural tissu…

AdultAmyloidPathologymedicine.medical_specialtyBatten diseaseAdolescentAmyloidImmunocytochemistryPathology and Forensic MedicineLipofuscinEpitopes03 medical and health sciencesCellular and Molecular Neuroscience0302 clinical medicineNeuronal Ceroid-LipofuscinosesAmyloid precursor proteinmedicineHumansSenile plaquesChildAged030304 developmental biology0303 health sciencesAmyloid beta-PeptidesbiologyAntibodies MonoclonalBrainInfantMiddle Agedmedicine.diseaseImmunohistochemistryMolecular biology3. Good healthChild Preschoolbiology.proteinNeuronal ceroid lipofuscinosisNeurology (clinical)Protein Processing Post-Translational030217 neurology & neurosurgeryImmunostainingActa Neuropathologica
researchProduct

The 9-O-acetylated disialosyl carbohydrate sequence of CDw60 is a marker on activated human B lymphocytes

1998

Gangliosides with a terminal 9-O-acetylated disialosyl group (CDw60 structures) show a restricted surface expression on human leukocytes. Hithereto, they have only been detected on subpopulations of human T lymphocytes. Using the defined CDw60 antibody UM4D4 and two new antibodies with preferential CDw60 activities, F6 and Z17, we demonstrate for the first time that CDw60 is an activation marker on human B lymphocytes. In vitro phorbol ester-stimulated human peripheral blood B lymphocytes as well as in vivo activated tonsillar B lymphocytes became CDw60 positive. CDw60 expression of these cells exceeds that of resting and activated T-lymphocytes.

AdultAntigens Differentiation T-Lymphocytemedicine.drug_classMolecular Sequence DataImmunologyLymphocyte ActivationMonoclonal antibodyStructure-Activity Relationshipchemistry.chemical_compoundAntigenAntigens CDPolysaccharidesIn vivomedicineHumansImmunology and AllergyStructure–activity relationshipB-LymphocytesbiologyAntibodies MonoclonalAcetylationMiddle AgedMolecular biologyIn vitroCarbohydrate SequenceBiochemistrychemistryAcetylationbiology.proteinPhorbolAntibodyBiomarkersImmunology Letters
researchProduct

Low bcl-2 expression and increased spontaneous apoptosis in T-lymphocytes from newly-diagnosed IDDM patients.

1995

The bcl-2 gene product has been shown to regulate apoptotic cell death, and its dysregulation has been shown to induce several abnormalities in the immune system. No data exist regarding bcl-2 expression in autoimmune diseases, such as human insulin-dependent diabetes mellitus (IDDM). We investigated bcl-2 protein expression by testing T lymphocytes from 15 newly-diagnosed (3 weeks) IDDM patients in comparison to 10 age-matched control subjects. The expression of bcl-2 on CD3+ lymphocyte subsets was investigated after membrane permeabilization by two- or three-colour immunofluorescence. When the percentage and mean fluorescence intensity (MFI) of bcl-2+/CD3+ cells from normal individuals an…

AdultBlood GlucoseMaleProgrammed cell deathmedicine.medical_specialtyAdolescentCD3 ComplexEndocrinology Diabetes and MetabolismLymphocyteCD3T-LymphocytesGene ExpressionApoptosisBiologychemistry.chemical_compoundImmune systemAntigens CDReference ValuesRisk FactorsT-Lymphocyte SubsetsInternal medicineProto-Oncogene ProteinsInternal MedicinemedicineHumansFamilyPropidium iodideAutoantibodiesAutoimmune diseaseGlycated HemoglobinT lymphocytemedicine.diseaseFlow Cytometrymedicine.anatomical_structureEndocrinologyDiabetes Mellitus Type 1chemistryProto-Oncogene Proteins c-bcl-2ApoptosisCase-Control Studiesbiology.proteinFemaleDiabetologia
researchProduct

SARS-CoV-2-specific Cell-mediated Immunity in Kidney Transplant Recipients Recovered From COVID-19.

2021

BACKGROUND: The magnitude and kinetics of severe acute respiratory syndrome coronavirus 2-specific cell-mediated immunity (SARS-CoV-2-CMI) in kidney transplant (KT) recipients remain largely unknown. METHODS: We enumerated SARS-CoV-2-specific interferon-I³-producing CD69+ CD4+ and CD8+ T cells at months 4 and 6 from the diagnosis of coronavirus disease 2019 (COVID-19) in 21 KT recipients by intracellular cytokine staining. Overlapping peptides encompassing the SARS-CoV-2 spike (S) glycoprotein N-terminal 1- to 643-amino acid sequence and the membrane protein were used as stimulus. SARS-CoV-2 IgG antibodies targeting the S1 protein were assessed by ELISA at month 6. RESULTS: Detectable (≥0.1…

AdultCD4-Positive T-LymphocytesGraft RejectionMalemedicine.medical_specialty030230 surgeryCD8-Positive T-LymphocytesAntibodies Monoclonal HumanizedGastroenterology03 medical and health sciencesImmunocompromised HostInterferon-gamma0302 clinical medicineCOVID-19 TestingImmunityInternal medicinemedicineHumansInterferon gammaskin and connective tissue diseasesKidney transplantationAgedTransplantationImmunity Cellularbiologybusiness.industrySARS-CoV-2CD69COVID-19Middle Agedmedicine.diseaseKidney TransplantationTacrolimusTransplant RecipientsCOVID-19 Drug TreatmentMonoclonalbiology.protein030211 gastroenterology & hepatologyFemaleAntibodybusinessCD8Immunosuppressive Agentsmedicine.drugFollow-Up StudiesTransplantation
researchProduct

Interleukin-9 over-expression and T helper 9 polarization in systemic sclerosis patients.

2017

Summary T helper 9 (Th9) cells and interleukin (IL)-9 are involved in the pathogenesis of several autoimmune diseases. The exact role of IL-9 and Th9 cells in patients with systemic sclerosis (SSc) have not yet been studied adequately. IL-9, IL-9R, transcription factor PU.1 (PU.1), IL-4, thymic stromal lymphopoietin (TSLP) and transforming growth factor (TGF)-β expression were assessed in skin and kidney biopsies of SSc patients and healthy controls (HC) by immunohistochemistry (IHC). The cellular source of IL-9 was also analysed by confocal microscopy analysis. Peripheral IL-9-producing cells were also studied by flow cytometry. The functional relevance of IL-9 increased expression in SSc …

AdultCD4-Positive T-LymphocytesMale0301 basic medicineIL-9 ILC2 systemic sclerosis Th9Thymic stromal lymphopoietinNeutrophilsImmunologyExtracellular TrapsPeripheral blood mononuclear cellFlow cytometryILC2Pathogenesis03 medical and health sciencesThymic Stromal LymphopoietinTransforming Growth Factor betaProto-Oncogene ProteinsmedicineHumansImmunology and AllergyTh9Interleukin 9Mast CellsAutoantibodiesSkinReceptors Interleukin-9B-LymphocytesScleroderma Systemicmedicine.diagnostic_testintegumentary systembusiness.industryInterleukin-9InterleukinCell DifferentiationOriginal ArticlesNeutrophil extracellular trapsMiddle AgedIL-9Settore MED/16 - Reumatologia030104 developmental biologyImmunologyTrans-ActivatorsCytokinesImmunohistochemistryFemaleInterleukin-4businesssystemic sclerosi
researchProduct